Publikationsdatenbank

Filter zurücksetzen
Titel
Studie
Jahr

705 patients with metastatic breast cancer treated with nab-paclitaxel: Results of the non-interventional study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhardt, S., Harde, J., Marschner, N. 2018.

Indikation: Mammakarzinom; Veranstaltung: DKK; Journal:

NABUCCO
2018

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.

Schuette, W., Schirmacher, P., Eberhardt, W.E.E., Dietel, M., Zirrgiebel, U., Muehlenhoff, L., Thomas, M., 2018.

BMC Cancer 18, 135. doi:10.1186/s12885-018-4032-3

Indikation: Bronchialkarzinom; Veranstaltung: -; Journal: BMC Cancer

REASON
2018

Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study.

Dörfel, S., Steffens, C.-C., Meyer, D., Tesch, H., Kruggel, L., Frank, M., Jänicke, M., Marschner, M. 2017.

Breast Cancer, 4 December 2017, 1–9. https://doi.org/10.1007/s12282-017-0823-7.

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer

TMK
2017

Molecular testing and first-line treatment of patients with NSCLC. First results from the German CRISP study (AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Nusch, A., Reiser, M., Losem, C., Ketzler-Henkel, Zahn, M., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., deWit, M., Metzenmacher, M., Waller, C., Kern, J., Weichert, W., Sebastian, M., Thomas, M., 2017.

IASLC World Conference (Yokohama) (P3.01-088).

Indikation: Bronchialkarzinom; Veranstaltung: IASLC (WCLC); Journal: -

CRISP
2017

Clinical Research platform Into molecular testing, treatment and outcome of non-Small cell lung carcinoma Patients (CRISP): a prospective German Registry in stage IV NSCLC AIO-TRK-0315).

Griesinger, F., Eberhardt, W., Marschner, N., Jaenicke, M., Fleitz, A., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Schirmacher, P., Sebastian, M., Thomas, M., 2017.

7th European Lung Cancer Conference (ELCC) (125P).

Indikation: Bronchialkarzinom; Veranstaltung: ELCC (IASLC); Journal: -

CRISP
2017

Cisplatin vs. carboplatin in routine treatment of advanced non-small cell lung cancer – results from the prospective German TLK cohort study.

von Verschuer, U., Schnell, R., Zahn, M.-O., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P600), 174.

Indikation: Bronchialkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLK
2017

Treatment reality and outcome data of patients with advanced papillary cell carcinoma – data from the German prospective RCC-Registry.

Staehler, M., Goebell, P., Müller, L., Overkamp, F., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P339), 96.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TNK
2017

Systemic palliativ treatment and outcome in later lines in patients with metastatic colorectal cancer – Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK).

Schnell, R., Uhlig, J., Eggers, E., Jänicke, M., Fleitz, A., Wetzel, N., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P587).

Indikation: Kolorektalkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TKK
2017

How much does fatigue, pain and treatment time interfere with daily life of patients with breast cancer? – Data from the MaLife-Project.

Marschner, N., Scholz, H., Behringer, J., Frank, M., Kruggel, L., Jänicke, M., for the TMK Registry Group, 2017.

Oncol Res Treat 40(suppl 3)(V796), 226. doi:10.1159/000479566

Indikation: Mammakarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TMK
2017

Treatment of patients with multiple myeloma selected for high-dose chemotherapy and autologous stem cell transplantation – Data from the German prospective TLN Registry.

Knauf, W., Abenhardt, W., Tamm, I., Anhuf, J., Grugel, R., Harde, J., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P608), 178.

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TLN
2017

Treatment sequences in patients with advanced or metastatic pancreatic cancer in German outpatient cancer centers – data from the TPK clinical cohort study.

Hegewisch-Becker, S., Aldaoud, A., Lerchenmüller, C., Scheiner-Sparna, R., Jänicke, M., Hamm, D., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(P825), 235.

Indikation: Pankreaskarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TPK
2017

Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry.

Goebell, P.J., Müller, L., Staehler, M., Müller, Frank, M., Kruggel, L., Jänicke, M., Marschner, N., 2017.

Oncol Res Treat 40 (suppl 3)(V420), 114.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

TNK
2017

Real world effectiveness and safety of pazopanib and everolimus in metastatic renal cell carcinoma: first interim analysis of the PAZOREAL study.

Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Goebell, 2017.

Oncol Res Treat 40 (suppl 3)(P343), 97–98.

Indikation: Nierenzellkarzinom; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

PAZOREAL
2017

German PASS (GS-DE-312-1750) – A prospective non-interventional post-authorization safety study (PASS) of idelalisib in Germany.

Abenhardt, W., Knauf, W., Eissmann, P., Hucke, N., van Troostenburg, A., Watzke, S., Hoechstetter, M., Rummel, M., 2017.

Oncol Res Treat 40 (suppl 3)(P524), 139–140.

Indikation: Hämoblastosen; Veranstaltung: DGHO; Journal: Oncology Research and Treatment

IDELA
2017

Application study of the EQ-5D-5L in Oncology: Linking self-reported quality of life of patients with metastatic colorectal cancer to clinical data from a German tumor registry.

Borchert, K., Jacob, C., Wetzel, N., Jänicke, M., Eggers, E., Sauer, A., Marschner, N., Meise, D., Altevers, J., Mittendorf, T., Braun, S., Greiner, W., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Kolorektalkarzinom; Veranstaltung: ISPOR; Journal: -

TKK
2017

Clinical Comparison of first-line platin chemotherapy regimens in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) using German registry data.

Haas, J., Meise, D., Ogbonnaya, A., Eaddy, M., Daeßler, K., Sandner, R., Binninger, A., Jaenicke, M., Chiabudini, M., Marschner, N., 2017.

ISPOR 20th Annual European Congress. Cancer: Clinical Outcomes Studies.

Indikation: Bronchialkarzinom; Veranstaltung: ISPOR; Journal: -

TLK
2017

Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma – data from the German prospective RCC-Registry.

Staehler, M., Müller, L., Goebell, P. J., Overkamp, F., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., for the RCC Registry group, 2017.

Ann Oncol 28(Suppl.5)(909P).

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

TNK
2017

Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry.

Goebell, P. J., Müller, L., Staehler, M., Müller, M., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., for the RCC Registry group, 2017.

Ann Oncol 28(Suppl.5)(902P). doi:10.1093/annonc/mdx365

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

TNK
2017

Comparison of platinum agents cisplatin and carboplatin in routine treatment of advanced NSCLC – results from prospective German TLK cohort study.

von Verschuer, U., Schnell, R., Zahn, M.-O., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Ann Oncol 28 (suppl 5)(1370P), 490.

Indikation: Bronchialkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

TLK
2017

CRISP
2017

Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventinal study NABUCCO.

Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhart, S., Harde, J., Marschner, N., 2017.

Ann Oncol 28 (Supplement 5)(293P), 97. doi:10.1093/annonc/mdx365

Indikation: Mammakarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

NABUCCO
2017

Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of Sorafenib-Pazopanib versus Pazopanib-Sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II).

Retz, M., Bedke, J., Herrmann, E., Grimm, M., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis, M., Beeker, A., Frank, M., Gschwend, J., 2017.

Ann Oncol 28 (Supplement 5)(8450), v295–v329. doi:10.1093/annonc/mdx371

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

SWITCH II
2017

Interim Results from PAZOREAL: A Non-interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changine mRCC Treatment Landscape.

Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehness, R., Klein, D., Medinger, T., Goebell, P., 2017.

Ann Oncol 28 (Supplement 5)(899P), 318–319. doi:10.1093/annonc/mdx371

Indikation: Nierenzellkarzinom; Veranstaltung: ESMO; Journal: Annals of Oncology

PAZOREAL
2017

Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC).

Woopen, H., Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Sehouli, J., 2017.

Ann Oncol 28 (Supplement 5)(956P), 340. doi:10.1093/annonc/mdx372

Indikation: Sonstige; Veranstaltung: ESMO; Journal: Annals of Oncology

OTILIA
2017

Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC).

Sehouli, J., Mustea, A., Oskay-Özcelik, G., Gabowski, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Wimberger, P., 2017.

Ann Oncol 28 (Supplement 5)(958P), 341. doi:10.1093/annonc/mdx372

Indikation: Sonstige; Veranstaltung: ESMO; Journal: Annals of Oncology

OTILIA
2017

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).

Decker, T., Overkamp, F., Rösel, S., Nusch, A., Göhler, T., Indorf, M., Sahlmann, J., Trarbach, T., 2017.

BMC Cancer 17(1), 499. doi:10.1186/s12885-017-3492-1

Indikation: Mammakarzinom; Veranstaltung: -; Journal: BMC Cancer

PASO
2017

Routine treatment and outcome of breast cancer in younger versus elderly patients: results from the SENORA project of the prospective German TMK cohort study.

Fietz, T., Zahn, M.-O., Köhler, A., Engel, E., Frank, M., Kruggel, L., Jänicke, M., Marschner, N., Cancer), 2017.

Breast Cancer Res Treat 1–12. doi:10.1007/s10549-017-4534-8

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer Research and Treatment

TMK
2017

Was können Registerdaten bei der Nutzenbewertung leisten?

Marschner, N., Jänicke, M., 2017.

Ärztezeitung, Schriftenreihe Interdisziplinäre Plattform zur Nutzenbewertung „Lücken in der Evidenz – was leisten Registerdaten?“ Heft 5, September 2017, ISSN 2364-916X

Indikation: Sonstige; Veranstaltung: -; Journal: Hefte der Interdisziplinären Plattform zur Nutzenbewertung

Registerübergreifend
2017

Die Bedeutung von klinischen Tumorregistern.

Marschner, N., Kaiser-Osterhues, A., 2017.

Im Focus Onkologie 20(9), 42–44. doi:10.1007/s15015-017-3513-6

Indikation: Sonstige; Veranstaltung: -; Journal: Im Focus Onkologie

Registerübergreifend
2017

Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort study.

Verschuer, U. von, Schnell, R., Tessen, H.W., Eggert, J., Binninger, A., Spring, L., Jänicke, M., Marschner, N., 2017.

Lung Cancer. 2017 Aug 22. pii: S0169-5002(17)30419-1. doi: 10.1016/j.lungcan.2017.07.031

Indikation: Bronchialkarzinom; Veranstaltung: -; Journal: Lung Cancer

TLK
2017

Palliative systemic therapy and overall survival of 1,395 patients with advanced breast cancer – results from the prospective German TMK cohort study.

Fietz, T., Tesch, H., Rauh, J., Boller, E., Kruggel, L., Jänicke, M., Marschner, N., 2017.

The Breast 34, 122–130. doi:http://dx.doi.org/10.1016/j.breast.2017.05.014

Indikation: Mammakarzinom; Veranstaltung: -; Journal: The Breast

TMK
2017

Predicting early treatment discontinuation and effectiveness in bevacizumab-treated patients with advanced ovarian cancer: Exploratory analyses of the OTILIA study (on behalf of NOGGO)

Wimberger, P., Woopen, H., Mustea, A., Oskay-Oezcelik, G., Keller, M., Harde, J., Richter, R., Wegenaer, A., Klawitter, S., Tomé, O., Sehouli, J., 2017.

ESGO7–0321 (PS19)

Indikation: Sonstige; Veranstaltung: ESGO; Journal: -

OTILIA
2017

Routine clinical use of nab-paclitaxel for advanced / metastatic breast cancer in Germany: Final results of the prospective observational study NABUCCO.

Schroeder, J., Potthoff, K., Salat, C., Soeling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., Marschner, N., 2017.

J Clin Oncol 35(suppl; abstr e12555). doi:10.1200/JCO.2017.35.15_suppl.e12555

Indikation: Mammakarzinom; Veranstaltung: ASCO; Journal: Journal of Clinical Oncology

NABUCCO
2017

Persistent impairments 3 years after (neo)adjuvant chemotherapy for breast cancer – results from the MaTox project.

Hurtz, H.-J., Tesch, H., Göhler, T., Hutzschenreuter, U., Harde, J., Kruggel, L., Jänicke, M., Marschner, N., TMK-Group (Tumour Registry Breast Cancer), 2017.

Breast Cancer Res Treat. 2017 Jul 5. doi: 10.1007/s10549-017-4365-7

Indikation: Mammakarzinom; Veranstaltung: -; Journal: Breast Cancer Research and Treatment

TMK
2017

The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape.

Goebell, P.J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehneß, R., Welslau, M., 2017.

Future Oncol 0(0). doi:10.2217/fon-2017-0083 (epup ahead of print)

Indikation: Nierenzellkarzinom; Veranstaltung: -; Journal: Future Oncology

PAZOREAL
2017

Treatment and pattern of bone metastases in 1094 patients with advanced breast cancer – Results from the prospective German Tumour Registry Breast Cancer cohort study.

Schröder, J., Fietz, T., Köhler, A., Petersen, V., Tesch, H., Spring, L., Fleitz, A., Jänicke, M., Marschner, N., 2017.

Eur J Cancer 79, 139–148. doi:10.1016/j.ejca.2017.03.031

Indikation: Mammakarzinom; Veranstaltung: -; Journal: European Journal of Cancer

TMK
2017

Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO-TRK-0315.

Griesinger, F., Eberhardt, W., Marschner, N., Jänicke, M., Hipper, A., Karatas, A., Sebastian, M., Thomas, M., Schirmacher, P., 2017.

J Thorac Oncol 12(1)(MA08.02), S385. doi:10.1016/j.jtho.2016.11.435

Indikation: Bronchialkarzinom; Veranstaltung: ELCC (IASLC); Journal: Journal of Thoracic Oncology

CRISP
2017

Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.

Schimanski, C.C., Staib, F., Göhler, T., Hebart, H., Heike, M., Neise, M., Rudi, J., Geer, T., Dingeldein, G., Lang, C., Ehscheidt, P., Flohr, T., Josten, K.M., Karthaus, M., Schmittel, A., Wierecky, J., Boller, E., Indorf, M., Wörns, M.-A., Galle, P.R., Moehler, M., 2017.

J. Cancer Res. Clin. Oncol. 143(6), 1023–1034. doi:10.1007/s00432-017-2344-3

Indikation: Kolorektalkarzinom; Veranstaltung: -; Journal: Journal of Cancer Research and Clinical Oncology

DERMATUX
2017

Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.

Marschner, N., Müller, L., Münch, A., Blumenstengel, K., Hutzschenreuter, U., Busies, S., 2017.

J Oncol Pharm Pract 23(4), 288–295. doi:10.1177/1078155216632379

Indikation: Nierenzellkarzinom; Veranstaltung: -; Journal: Journal Oncology Pharmacy Practice

TNK
2017

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma – a phase II trial.

Mey, U.J.M., Brugger, W., Schwarb, H., Pederiva, S., Schwarzer, A., Dechow, T., Jehner, P., Rauh, J., Taverna, C.J., Schmid, M., Schmidt-Hieber, M., Doerfel, S., Fischer, N., Ruefer, A., Ziske, C., Knauf, W., Cathomas, R., von Moos, R., Hitz, F., Sauter, R., Hiendlmeyer, E., Cantoni, N., Bargetzi, M., Driessen, C., 2016.

Br. J. Haematol. 176(5), 770–782. doi:10.1111/bjh.14481

Indikation: Hämoblastosen; Veranstaltung: -; Journal: British Journal of Hematology

BRd
2016

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com